drugset
drugset / Trial / NCT04007198

A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma

NCT04007198 ↗

Phase 1 Completed 18 enrolled Biocon Limited Equillium AUS Pty Ltd · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.

Timeline

Start
2019-06-20
Primary completion
2021-10-12
Completion
2021-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Itolizumab Monoclonal antibody — Subcutaneous

Indications

asthma